fashion -WSS

fashion

author：focus 2025-09-29 21:20:55 - browse：918

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Britney Spears to release memoir, 'The Woman In Me,' later this year

WSS

Stroke deaths set to near 10 million globally by 2050

Physician executives need more than on

Chemotherapy drug shortage eases slightly but still widespread

Bill would stop addiction treatment from triggering child abuse inquiry

Chemotherapy drug shortage eases slightly but still widespread

After half a century, Israel moves to evict squatter from his cave home on the beach

entertainment

fashion

Wikipedia

In Memoriam: Notable people who died in 2023

Sickle cell gene therapy cures need to be accessible in Africa

ChatGPT in medicine: STAT answers readers' burning questions

China sends large group of warplanes, navy ships towards Taiwan in forceful display

What does generative AI mean for health care? We asked experts

Colorectal cancer study finds potential in overlooked immune cell

Activists slam private health insurers over coverage restrictions

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

After affirmative action ruling, medical educators look to 'holistic review'

VC firm General Catalyst wants to buy a health system

focus

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Inflation cooled significantly in June, bringing price hikes close to normal levels

Phenylephrine and the overlooked value of the placebo effect

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

EU fines Illumina $475 million over Grail acquisition

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

leisure time

explore

hotspot

entertainment